🔗 Share this article

While the US proceeds with historic adjustments to its vaccine guidelines, a particular individual appears in a surprising turn: Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about Covid vaccines in the global health crisis and has focused upon possible fatalities following Covid vaccination in her recent tenure at the Food and Drug Administration.

Scheduled Shifts to Pediatric Vaccine Schedule

Public health authorities had intended to announce major changes to the childhood immunization program in December, synchronizing the US with the Danish immunization schedule, according to reports – a substantial departure that would put the US out of step with much of the international standard with little proof for benefit. The announcement has been pushed back until the next year.

Rather than the top vaccines chief, Dr. Høeg is listed to speak at the event. She was recently named interim head of the FDA’s drug evaluation center, the fifth appointee to lead the division this year.

A Shift at the Agency

This interim role may indicate a tighter collaboration between the drug and biologics centers as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a greater focus upon reevaluating long-standing vaccines at the FDA.

The new acting director has frequently advocated for ending some childhood shot schedules in the US to become more similar to Denmark's approach, a society with nationalized medicine and a population about the population of Wisconsin’s.

In her initial statements, she has continued to focus on vaccines – typically the purview of Dr. Prasad, head of the FDA’s CBER – as opposed to medication approval.

Concerns Over Background

Dr. Høeg has no obvious experience in pharmaceutical research, approval processes or administrative roles, which has been customary for former directors of the biologics center. She has served at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“It seems she lacks to have any of the qualifications” for running the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in leading a major agency. She has no expertise in industry regulation.”

Previous directors of the center would “grasp legal statutes and the research of medication creation”, noted a former acting FDA commissioner. “Frankly, she has not acquired the kind of background that previous people who ran the center have had.”

This division has an vast portfolio at the agency, Woodcock stated.

“Everybody just focuses on the innovative therapies, but the generic drug division authorizes numerous generic drugs. There is also a biosimilars program, OTC medication office and so forth, and every single one have to be looked after,” Dr. Woodcock said. “The area you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Furthermore, a substantial leadership aspect to the job, which oversees more than 5,000 personnel. “It’s a enormous management job, if you execute it properly,” the former official added.

Official Statement and Disputed Programs

In response to concerns about Dr. Høeg's qualifications and whether this appointment signifies more teamwork among agency officials on immunizations, a press secretary responded that the “inquiries are based on incorrect premises”.

“Her resume is consistent with the functions of her position,” the official stated, pointing to the period Høeg spent advising the agency head on “drug safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As acting director, Dr. Høeg takes over the commissioner’s new expedited review system, a disputed expedited drug-approval program that reportedly concerned her former heads. “How are these drugs being chosen for this fast-track system? Who makes the calls?” Dr. Howard questioned. “There is a lot of lack of transparency happening at the FDA right now.”

In general, he said, “the agency looks to be trending towards less stringent rules of most medications, except for shots.”

Documented Track Record on Immunizations

Regarding immunizations, Høeg has a more documented, if troubling, past, critics said. She released a research paper using unconfirmed public submissions to assess the rate of myocarditis after Covid vaccination. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccines are more dangerous than they are.

Part of her “desired changes” for the current administration encompassed changing regulations for novel immunizations and discontinuing “unnecessary” vaccines, she remarked following the vote on a online show. At the FDA, Høeg has reportedly floated the idea of barring teenage boys from receiving COVID-19 vaccines.

“She’s an complete dogmatist who commences with her conclusions and reverse-engineers to retrofit the data in a very misleading, untruthful way,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg became part of other skeptics, {like|